Literature DB >> 25561765

Impact of jejunostomy during esophagectomy for cancer on health related quality of life.

Marco Scarpa1, Francesco Cavallin1, Giulia Noaro1, Eleonora Pinto1, Rita Alfieri1, Matteo Cagol1, Carlo Castoro1.   

Abstract

BACKGROUND: The aim of this study was to evaluate the impact of jejunostomy during esophagectomy for cancer on postoperative health-related quality of life (HRQL).
METHODS: We evaluate all consecutive patients who underwent esophagectomy for cancer at the surgical oncology unit of the Veneto Institute of Oncology (IOV-IRCCS) between January 2008 and March 2014. The primary outcome was HRQL, which was assessed using nine scales of EORTC C30 and OES18 questionnaires. General linear models were estimated to evaluate mean score difference (MD) of each selected scale in patients with and without jejunostomy, adjusting for clinically relevant confounders. The secondary outcomes were morbidity, hospital stay, postoperative weight loss and postoperative albumin impairment.
RESULTS: Jejunostomy was performed in 40 on 109 patients (41.3%) who participated in quality of life investigation. A clinically and statistically significantly worse eating at admission (P=0.009) became not clinically significant at 3 months after surgery (MD =9.1). Jejunostomy was associated to clinically and statistically significantly poorer emotional function (EF) at 3 months after surgery (MD =-15.6; P=0.04). Hospital stay was longer in jejunostomy group (median, 20 vs. 17 days, P=0.02).
CONCLUSIONS: In our series patients who had a jejunostomy during esophagectomy had been selected for their risk for postoperative complication. However, their postoperative outcome was actually similar compared to those without jejunostomy. Nevertheless, jejunostomy was associated to clinically and statistically significantly poorer EF at 3 months after surgery. Therefore, patient candidate to esophagectomy and feeding jejunostomy should receive additional psychological support.

Entities:  

Keywords:  Health-related quality of life (HRQL); esophageal cancer; esophagectomy; jejunostomy

Year:  2014        PMID: 25561765      PMCID: PMC4279207          DOI: 10.3978/j.issn.1000-9604.2014.12.16

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  29 in total

Review 1.  Postoperative mortality following oesophagectomy and problems in reporting its rate.

Authors:  G G Jamieson; G Mathew; R Ludemann; J Wayman; J C Myers; P G Devitt
Journal:  Br J Surg       Date:  2004-08       Impact factor: 6.939

2.  Risk factors for complications after esophageal cancer resection: a prospective population-based study in Sweden.

Authors:  Pernilla Viklund; Mats Lindblad; Ming Lu; Weimin Ye; Jan Johansson; Jesper Lagergren
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

3.  Prospective evaluation of quality of life in patients with localized oesophageal cancer treated by multimodality therapy or surgery alone.

Authors:  J V Reynolds; R McLaughlin; J Moore; S Rowley; N Ravi; P J Byrne
Journal:  Br J Surg       Date:  2006-09       Impact factor: 6.939

Review 4.  Systematic review of health-related quality of life after esophagectomy for esophageal cancer.

Authors:  Marco Scarpa; Stefano Valente; Rita Alfieri; Matteo Cagol; Giorgio Diamantis; Ermanno Ancona; Carlo Castoro
Journal:  World J Gastroenterol       Date:  2011-11-14       Impact factor: 5.742

5.  Supportive nutrition on recovery of metabolism, nutritional state, health-related quality of life, and exercise capacity after major surgery: a randomized study.

Authors:  Anders Hyltander; Ingvar Bosaeus; Jan Svedlund; Bengt Liedman; Irene Hugosson; Ola Wallengren; Ulla Olsson; Erik Johnsson; Srdjan Kostic; Annika Henningsson; Ulla Körner; Lars Lundell; Kent Lundholm
Journal:  Clin Gastroenterol Hepatol       Date:  2005-05       Impact factor: 11.382

6.  Overweight patients operated on for cancer of the esophagus survive longer than normal-weight patients.

Authors:  Marco Scarpa; Matteo Cagol; Silvia Bettini; Rita Alfieri; Amedeo Carraro; Francesco Cavallin; Elisabetta Trevellin; Luca M Saadeh; Alberto Ruol; Roberto Vettor; Ermanno Ancona; Carlo Castoro
Journal:  J Gastrointest Surg       Date:  2012-09-13       Impact factor: 3.452

7.  Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial.

Authors:  B L D M Brücher; H J Stein; F Zimmermann; M Werner; M Sarbia; R Busch; H J Dittler; M Molls; U Fink; J R Siewert
Journal:  Eur J Surg Oncol       Date:  2004-11       Impact factor: 4.424

Review 8.  Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus.

Authors:  Johannes Zacherl; Andreas Sendler; Hubert J Stein; Katja Ott; Marcus Feith; Raimund Jakesz; J Rüdiger Siewert; Ulrich Fink
Journal:  World J Surg       Date:  2003-08-28       Impact factor: 3.352

9.  Quality of life during potentially curative treatment for locally advanced oesophageal cancer.

Authors:  K N L Avery; C Metcalfe; C P Barham; D Alderson; S J Falk; J M Blazeby
Journal:  Br J Surg       Date:  2007-11       Impact factor: 6.939

10.  Cancer statistics, 2003.

Authors:  Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2003 Jan-Feb       Impact factor: 508.702

View more
  2 in total

1.  Utility of feeding jejunostomy in patients with esophageal cancer undergoing esophagectomy with a high risk of anastomotic leakage.

Authors:  Weitao Zhuang; Hansheng Wu; Huiling Liu; Shujie Huang; Yinghong Wu; Cheng Deng; Dan Tian; Zihao Zhou; Ruiqing Shi; Gang Chen; Guillaume Piessen; Puja G Khaitan; Kazuo Koyanagi; Soji Ozawa; Guibin Qiao
Journal:  J Gastrointest Oncol       Date:  2021-04

2.  QOLEC2: a randomized controlled trial on nutritional and respiratory counseling after esophagectomy for cancer.

Authors:  Eleonora Pinto; Maria Teresa Nardi; Carlo Castoro; Marco Scarpa; Rita Marchi; Francesco Cavallin; Rita Alfieri; Luca Saadeh; Matteo Cagol; Ilaria Baldan; Elisabetta Saraceni; Matteo Parotto; Fabio Baratto; Cristina Caberlotto; Andrea Vianello
Journal:  Support Care Cancer       Date:  2020-06-22       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.